OUR CORPORATE COMMITMENT
Our commitment is integrated into a defined A4CELL Business Circle: Execution, environmental protection, customer orientation, integrity, innovation, and team collaboration.
To offer powerful and innova- tive tools to the Pharma and Biotech industry for monitoring and enhancing the single cell analysis studies into to drug discovery and development.
To develop devices ready to be applied in different biomedicine fields to enhance global competitiveness for the pharma, biotech, and R&D sectors.
Teamwork is the principal tool for all A4cell. We are especially encouraged to find sustainable solutions by nano and biotechnology innovation for human and animal healthcare. We are motivated to collaborate with our customer to develop new and disruptive solutions for them.
A4cell’s company culture is based around improving services and products to our customers with the responsibility to solve
MEET OUR TEAM
We are proud to introduce you our team, an great combination of skills and experience that results in a solid, balanced structure.
We are a company of enthusiastic people in love with nano-biotechnological research and development devoted to providing
innovative solutions for a wide range of biomedicine fields.
Born in 2018 because of a disruptive project carried out by a research team from the Institute of Microelectronics of Barcelona (IMB-CSIC), led by Dr. Jose Antonio Plaza and Dr. Jaume Esteve.
Scientific promoters, management staff, and investors make up our shareholders structure
Imagine having an eye inside
a living cell and study
whatever process is
happening in that instant!
It´s always better when you smile!
A4CELL SCIENTIFIC ADVISOR COMMITTEE
A high-profile Advisory Team, always up-to-date to the latest developments in science.
An expert opinion from the best advisors.
Jose Antonio Plaza
"The potential of the extraordinary small in biotechnology"
Jaume Esteve Tintó
“Bio and nanotechnology are merging and defining new paradigms”
J.P. Agusil Antonoff
"Microscopic tools, colossal questions"
"Pushing the limits of miniaturization"
BOARDS OF INVESTORS
Our majority partner, BeAble Capital SGEIC SA, Venture of reference in Science Equity (Technology Transfer funds focused on Deep Science), through its fund BeAble Innvierte Kets Fund, FCR, invest in Seed and Early Stage in the Industrial High Technology sector with the goal of transferring to society the technologies born in academic and research institutions in Spain and providing support for transforming breakthrough discoveries into products through start-ups.
We are a company of enthusiastic people in love with nanobiotechnological research and development devoted to providing innovative solutions for a wide range of biomedicine fields.
Chief Executive Officer
Vicepresident of Spanish Biotech Companies Association (ASEBIO)
Alberto Hernández Pinto
Chief Scientific Officer
Chief Technological Officer